PubMed 25816897

Referenced in: none

Automatically associated channels: TRP , TRPA , TRPA1 , TRPC , TRPC3 , TRPC4 , TRPC5 , TRPM , TRPM8 , TRPV , TRPV1 , TRPV3

Title: Identification and optimization of 2-aminobenzimidazole derivatives as novel inhibitors of TRPC4 and TRPC5 channels.

Authors: Yingmin Zhu, Yungang Lu, Chunrong Qu, Melissa Miller, Jinbin Tian, Dhananjay P Thakur, Jinmei Zhu, Zixin Deng, Xianming Hu, Meng Wu, Owen B McManus, Min Li, Xuechuan Hong, Michael X Zhu, Huai-Rong Luo

Journal, date & volume: Br. J. Pharmacol., 2015 Jul , 172, 3495-509

PubMed link: http://www.ncbi.nlm.nih.gov/pubmed/25816897

Abstract
Transient receptor potential canonical (TRPC) channels play important roles in a broad array of physiological functions and are involved in various diseases. However, due to a lack of potent subtype-specific inhibitors the exact roles of TRPC channels in physiological and pathophysiological conditions have not been elucidated.Using fluorescence membrane potential and Ca(2+) assays and electrophysiological recordings, we characterized new 2-aminobenzimidazole-based small molecule inhibitors of TRPC4 and TRPC5 channels identified from cell-based fluorescence high-throughput screening.The original compound, M084, was a potent inhibitor of both TRPC4 and TRPC5, but was also a weak inhibitor of TRPC3. Structural modifications of the lead compound resulted in the identification of analogues with improved potency and selectivity for TRPC4 and TRPC5 channels. The aminobenzimidazole derivatives rapidly inhibited the TRPC4- and TRPC5-mediated currents when applied from the extracellular side and this inhibition was independent of the mode of activation of these channels. The compounds effectively blocked the plateau potential mediated by TRPC4-containing channels in mouse lateral septal neurons, but did not affect the activity of heterologously expressed TRPA1, TRPM8, TRPV1 or TRPV3 channels or that of the native voltage-gated Na(+) , K(+) and Ca(2) (+) channels in dissociated neurons.The TRPC4/C5-selective inhibitors developed here represent novel and useful pharmaceutical tools for investigation of physiological and pathophysiological functions of TRPC4/C5 channels.